Blog

Filippo Gallina: PD-L1 testing in the context of neoadjuvant chemo-immunotherapy

Photo from Filippo Gallina/X

Aug 3, 2024, 08:51

Filippo Gallina: PD-L1 testing in the context of neoadjuvant chemo-immunotherapy

Filippo Gallina, Research Fellow at McGill University Health, shared his recent article on X:

“Happy to share those considerations published on Lung Cancer Journal about PD-L1 testing in the context of neoadjuvant chemo-immunotherapy. Thanks to all the co-authors!”

Title: Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC

Authors: Filippo Tommaso Gallina, Vittoria Balzano, Nicla Porciello, Riccardo Tajè, Daniele Forcella, Enrico Melis, Fabiana Letizia Cecere, Francesca Fusco, Simonetta Buglioni, Paolo Visca, Paola Nisticò, Federico Cappuzzo, Jonathan Spicer

Source: Filippo Gallina/X

cancer chemo-immunotherapy Fabiana Cecere Federico Cappuzzo Filippo Tommaso Gallina Jonathan Spicer Lung Cancer Journal Nicla Porciello OncoDaily Oncology PD-L1 testing Vittoria Balzano

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage